Ment preassociated with a gr Eren Dihydrofolate Reductase potential for EFS, PFS and OS associated. Data from the IRIS study showed long-term forecasters tic importance of early molecular response to imatinib in patients with newly diagnosed CML. The patients who achieved MMR at 18 months showed no Ver Change in AP / BC 7 years later Ter, with EFS of 95% at 7 years. In line with this finding, the durability of response is improved in patients with MMR early. The patients who had achieved MMR at 18 months only to lose a chance of 3% to 7 years, CCR, do not reach compared to a 26% risk for patients MMR early. W during the study, the rate of MMR increased in patients with CCyR htem 62% MMR at 12 months and 78% had achieved MMR at 18 months. Conversely, the proportion of patients with renal cell carcinoma, the MMR-ING within a 12 to 18 months, 33% to 17%. The German CML Study IV examines the link between the MMR vaccination at 12 months and survival rates after 3 years. Compared with no MMR at 12 months, reaching the MMR vaccination at 12 months was significantly bet ter with PFS and OS at 3 years, independent Ngig connected by the type of treatment. This is the first study to demonstrate a significant correlation between the performance of the MMR vaccination and improved PFS and OS. It turns out that the answers to three months before dict favorable long-term results. Guidelines currently define the optimal response to imatinib in ELN 3 months to MCyR or better. survival correlated in light of recent data reaches tion of molecular or cytogenetic response by 3 months of treatment significantly improved with imatinib, disease progression, and EFS, it can also be useful for clinicians to realize the answers are aimed low in the beginning of the process management . At present the evidence for the R Predictive of early response to dasatinib, nilotinib, or are limited, however, itis reasonable to expect a therapeutic benefit Similar as observed with imatinib. So far, show vorl INDICATIVE reports that, as with imatinib and achieved 2-log reduction of BCR-ABL transcripts of at least 3 months of nilotinib or dasa tinib treatment significantly predicted h Here probability of achieving CCR, MMR and CMR, and h survive here and the progression-free survival without failure. Particularly mentioned Is reasonable to point out to answer the deepest and fastest offer molecular Nilo tinib and dasatinib compared with imatinib observed intriguing clues to the nature of the differences that occur over time k can. Condense the information that molecular reactions k May have prognostic value. In fact, a molecular monitoring has r Both the National Comprehensive Cancer Network guidelines and the ELN, the h Ufigere recommended monitoring of BCR ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction. NCCN guidelines recommend qRT PCR every 3 months if a patient is to respond to development and to treat every 6 months three CCyR was achieved. Rising levels of BCR ABL transcript in a patient with MMR is a signal for an sp Tere offense ING qRT-PCR assay. ELN guidelines recommend BCR ABL levels monitored every 3 months until the MMR and is best CONFIRMS, then every 6 months thereafter. MMR at 18 months to define an optimal therapeutic response. Standardized, reliably SSIGE quantitative PCR for serial measurements of BCR ABL transcript levels optimize the monitoring of molecular.